KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Deffered Revenue (2016 - 2024)

Historic Non-Current Deffered Revenue for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2024 value amounting to $1.0 million.

  • Alnylam Pharmaceuticals' Non-Current Deffered Revenue fell 9948.39% to $1.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.0 million, marking a year-over-year decrease of 9948.39%. This contributed to the annual value of $188.2 million for FY2023, which is 289.8% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Non-Current Deffered Revenue of $1.0 million as of Q3 2024, which was down 9948.39% from $2.4 million recorded in Q2 2024.
  • Alnylam Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $306.1 million for Q1 2020, and its period low was $1.0 million during Q3 2024.
  • Its 5-year average for Non-Current Deffered Revenue is $180.9 million, with a median of $191.3 million in 2023.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Non-Current Deffered Revenue skyrocketed by 6394267.78% in 2020 and then crashed by 9948.39% in 2024.
  • Alnylam Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $225.1 million in 2020, then tumbled by 32.31% to $152.4 million in 2021, then increased by 27.19% to $193.8 million in 2022, then decreased by 2.9% to $188.2 million in 2023, then plummeted by 99.46% to $1.0 million in 2024.
  • Its Non-Current Deffered Revenue stands at $1.0 million for Q3 2024, versus $2.4 million for Q2 2024 and $185.5 million for Q1 2024.